The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug i
After years of stagnation in the treatment of neurodegenerative disorder amyotrophic lateral sclerosis (ALS), patients in the US could soon have two new treatment options – but their pricin
Amylyx Pharmaceuticals' efforts to bring its amyotrophic lateral sclerosis therapy AMX0035 to market in the US have run into some roadblocks, so an approval by Health Canada is a welcome re
Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements from the EMA.
